Feed KALA
KA

Kala Pharmaceuticals, Inc.

KALA · NASDAQ

$0.54 -6.78% (-$0.04)
1M -40.60%
Market Cap $10.5M
P/E Ratio -
Div. Yield -
ROE 187.45%

Bulios Fair Price

$0.81

49.8% upside

Trenutna cena

$0.54

Podcenjeno Poštena vrednost Precenjeno

Po podatkih Bulios Fair Price je delnica KALA trenutno podcenjena glede na svojo tržno ceno. Kako deluje?

Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?

Piotroski F-Score Weak
3/9
Valuation
100 /100
Cheap
P/B 1.16x
P/E N/A
EV/EBITDA N/A
Growth
0 /100
Declining
Book val. growth 28.29%
EPS growth N/A
Rev. growth N/A
Profitability
-
N/A
Gross margin N/A
Net margin N/A
Op. margin N/A
Quality
0 /100
Poor
ROIC 232.05%
ROE 187.45%
ROA 80.32%
Debt
69 /100
Low
Debt/Equity 0.00x
Current ratio 6.88x
Int. coverage -6.70x
Stability
62 /100
Moderate
Beta -2.29x
EPS volatility 9.39%
Profitable years 0

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o KALA
Online

O podjetju

Kala Pharmaceuticals, Inc. (Ticker: KALA) is a biotechnology company focused on the research and development of ophthalmic drugs. The company emphasizes innovative therapeutic approaches to eye diseases through its unique nanotechnology-based approach. Kala Pharmaceuticals is developing drugs designed to provide sustained release of therapeutic agents, which may improve the efficacy and convenience for patients. The company's focus includes indications such as dry eye disease and ocular surface inflammation. With the increasing awareness of the need for treating eye conditions, Kala Pharmaceuticals is well-positioned in the market and may offer an investment opportunity for those interested in the advancements of drugs and technologies in ophthalmology.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Biotechnology

CEO

Avi Minkowitz

Employees

6

Headquarters

Arlington

Prihajajoči dogodki

10 NOV.

Earnings

Upcoming earnings report

56d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.